Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984659 · ClinicalTrials.gov registry record · Phase 4
Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 366
- Enrollment target
NCT00984659 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 366 participants.
The verdict
NCT00984659, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 366 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities Questionnaire.
Interventions
- DRUG Placebo
- DRUG Salmeterol
- DRUG Fluticasone propionate/salmeterol combination product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2009-10-29 |
| Est. Completion | 2010-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00984659
The ClinicalTrials.gov registry entry for NCT00984659 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00984659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00984659 about?
NCT00984659 is a clinical study titled "Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease". The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities Questionnaire.
What is the current status of trial NCT00984659?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 366 participants. The study started on 2009-10-29. Estimated completion is 2010-07-01.
What interventions are being tested in trial NCT00984659?
The interventions under investigation include: Placebo (DRUG), Salmeterol (DRUG), Fluticasone propionate/salmeterol combination product (DRUG).
Who is sponsoring clinical trial NCT00984659?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.